<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="149649">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01883388</url>
  </required_header>
  <id_info>
    <org_study_id>RAM-NOVEL-211-2012</org_study_id>
    <nct_id>NCT01883388</nct_id>
  </id_info>
  <brief_title>NovellusDx Cancer Early Detection Blood Test- Clinical Trial</brief_title>
  <official_title>Assessing the Ability of An Innovative Screening Method To Identify Proteomic Changes In Cancer Patients- Protocol</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NovellusDx</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NovellusDx</source>
  <oversight_info>
    <authority>Israel: Ministry of Health</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      NovellusDx early detection test is a simple to perform blood test, which identifies the
      deregulated signaling pathways within the patient tumor based on  protein secretion to the
      blood, thus enabling early stage disease signature detection. The investigators' current
      clinical trial is focused on proving the main feature of NovellusDx's Early Detection Test-
      discriminating between cancer patients and healthy subjects.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>June 2013</start_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Number of Participants with a significant cancer fingerprint as measured by NovellusDX Cancer Early Detection test</measure>
    <time_frame>3.5 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>NovellusDX Cancer Early Detection test will identify participants with significant cancer fingerprint based on tumor protein secretion to the blood circulation in sick subjects.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Lung Cancer</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Healthy subjects and subjects with primary / relapsed lung cancer
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  subjects ages 18 and above ICF obtain

        Exclusion Criteria:

          -  none
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yishai Ofran, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rambam MC. Haematology Department</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Rambam MC</name>
      <address>
        <city>Haifa</city>
        <zip>31096</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yishay Ofran, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>June 2013</verification_date>
  <lastchanged_date>June 19, 2013</lastchanged_date>
  <firstreceived_date>June 17, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Lung Cancer</keyword>
  <keyword>blood sample</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
